Jun09

The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.

May28

Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”

May06

Exciting new preclinical data at the world’s foremost gene therapy conference shows the potential of Solid GT’s AAV micro-dystrophin gene replacement candidate in Duchenne muscular dystrophy (DMD).

The talent and commitment of the community

Solid believes powerful collaborations with the Duchenne muscular dystrophy community, which has worked tirelessly to find and fund potential therapies to combat  the disease, ensures the best chance of success.

Image: 
Navigation title: 
collaboration
Background video: 
Show particles: 
Show print button: 

Why I Joined Solid?

We sat down with the Solid team to learn what inspires them.

Image: 
Team
Navigation title: 
Meet the team
Background video: 
Show particles: 
Show print button: 

Corrective Therapies

Our corrective therapies platform is dedicated to the development of gene transfer candidates for Duchenne muscular dystrophy.

Image: 
Navigation title: 
Gene Transfer Development
Video: 
Background video: 
Show particles: 

Addressing secondary disorders

Navigation title: 
Disease Modifying Therapies
Background video: 
Images: 
Show particles: 

Mechanical Support & Devices

Wearable support for patients with Duchenne muscular dystrophy

Image: 
RickSRI
Navigation title: 
assistive devices
Background video: 
Show particles: 

Disease Modifying Therapies

Drug 1

Our Disease Modifying Therapies R&D initiative aims to rapidly and thoroughly test the diverse therapeutic approaches emerging out of academia and industry as a first step toward clinical development.

Drug 2

Our Disease Modifying Therapies R&D initiative aims to rapidly and thoroughly test the diverse therapeutic approaches emerging out of academia and industry as a first step toward clinical development.

Assistive devices

Solid Biosciences proudly partnered with Silicon Valley research group SRI International, Parent Project Muscular Dystrophy and other engineering and disease experts, to develop a soft, wearable assistive device for patients with DMD.

Pages

More information about Solid?

Please subscribe to receive our latest news